These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1325955)

  • 1. Inhibitory effect of suramin on receptor binding and cytotoxic activity of tumor necrosis factor alpha.
    Grazioli L; Alzani R; Ciomei M; Mariani M; Restivo A; Cozzi E; Marcucci F
    Int J Immunopharmacol; 1992 May; 14(4):637-42. PubMed ID: 1325955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of tumor necrosis factor-alpha (TNF-alpha)/TNF-alpha receptor binding by structural analogues of suramin.
    Mancini F; Toro CM; Mabilia M; Giannangeli M; Pinza M; Milanese C
    Biochem Pharmacol; 1999 Sep; 58(5):851-9. PubMed ID: 10449196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergism between human tumor necrosis factor and human interferon-alpha: effects on cells in culture.
    Orita K; Ando S; Kurimoto M
    Acta Med Okayama; 1987 Aug; 41(4):155-60. PubMed ID: 3661240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.
    Strassmann G; Fong M; Freter CE; Windsor S; D'Alessandro F; Nordan RP
    J Clin Invest; 1993 Nov; 92(5):2152-9. PubMed ID: 8227330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of suramin on human interferon alpha binding to cell receptors.
    Kandefer-Szerszeń M; Ruuth K; Lundgren E
    Arch Immunol Ther Exp (Warsz); 1997; 45(1):93-9. PubMed ID: 9090447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of suramin-induced deoligomerization of tumor necrosis factor alpha.
    Alzani R; Cozzi E; Corti A; Temponi M; Trizio D; Gigli M; Rizzo V
    Biochemistry; 1995 May; 34(19):6344-50. PubMed ID: 7756262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
    Regmi A; Fuson T; Yang X; Kays J; Moxham C; Zartler E; Chandrashekhar S; Galvin RJ
    Bone; 2005 Feb; 36(2):284-91. PubMed ID: 15780954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suramin induces deoligomerization of human tumor necrosis factor alpha.
    Alzani R; Corti A; Grazioli L; Cozzi E; Ghezzi P; Marcucci F
    J Biol Chem; 1993 Jun; 268(17):12526-9. PubMed ID: 8509393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suramin blocks the binding of interleukin-1 to its receptor and neutralizes IL-1 biological activities.
    Strassmann G; D'Alessandro F; Fong M; Nordan RP; Nickel P; Chizzonite R
    Int J Immunopharmacol; 1994 Nov; 16(11):931-9. PubMed ID: 7868298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
    Lopez Lopez R; van Rijswijk RE; Wagstaff J; Pinedo HM; Peters GJ
    Eur J Cancer; 1994; 30A(10):1545-9. PubMed ID: 7833116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin.
    Ellis V; Danø K
    Biochem J; 1993 Dec; 296 ( Pt 2)(Pt 2):505-10. PubMed ID: 8257443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suramin blocks binding of interleukin-4 to its receptors on human tumor cells and interleukin-4-induced mitogenic response.
    Leland P; Obiri N; Aggarwal BB; Puri RK
    Oncol Res; 1995; 7(5):227-35. PubMed ID: 8534928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop.
    Schrell UM; Gauer S; Kiesewetter F; Bickel A; Hren J; Adams EF; Fahlbusch R
    J Neurosurg; 1995 Apr; 82(4):600-7. PubMed ID: 7897522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice.
    Eichhorst ST; Krueger A; Müerköster S; Fas SC; Golks A; Gruetzner U; Schubert L; Opelz C; Bilzer M; Gerbes AL; Krammer PH
    Nat Med; 2004 Jun; 10(6):602-9. PubMed ID: 15146177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic regions of tumor necrosis factor alpha and their topographic relationships with structural/functional domains.
    Corti A; Fassina G; Marcucci F; Cassani G
    Mol Immunol; 1992 Apr; 29(4):471-9. PubMed ID: 1373465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of suramin on 125I-insulin-like growth factor-I binding to human meningiomas and on proliferation of meningioma cells.
    Tsutsumi K; Kitagawa N; Niwa M; Himeno A; Taniyama K; Shibata S
    J Neurosurg; 1994 Mar; 80(3):502-9. PubMed ID: 8113863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha.
    Kramer SM; Aggarwal BB; Eessalu TE; McCabe SM; Ferraiolo BL; Figari IS; Palladino MA
    Cancer Res; 1988 Feb; 48(4):920-5. PubMed ID: 2827889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction.
    Chang SY; Yu DS; Sherwood ER; Kozlowski JM; Lee C
    J Urol; 1992 Apr; 147(4):1147-50. PubMed ID: 1552613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies.
    Falcone A; Danesi R; Zaccaro L; Pieracci D; Pfanner E; Cianci C; Andreuccetti M; Malvaldi G; Del Tacca M; Conte PF
    Eur J Cancer; 1994; 30A(4):516-20. PubMed ID: 8018411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suramin inhibits bone resorption and reduces osteoblast number in a neonatal mouse calvarial bone resorption assay.
    Walther MM; Kragel PJ; Trahan E; Venzon D; Blair HC; Schlesinger PH; Jamai-Dow C; Ewing MW; Myers CE; Linehan WM
    Endocrinology; 1992 Nov; 131(5):2263-70. PubMed ID: 1425426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.